Respuestas rápidas
- ¿Para qué se usa Zidebactam dihydrate and cefepime hydrochloride?
- La etiqueta aprobada por la FDA (Zaynich, Wockhardt Suisse USA LLC, 16 de octubre de 2026) dice, en inglés: “ZAYNICH is a combination of cefepime, a cephalosporin antibacterial, and zidebactam, a beta-lactamase inhibitor and non-beta-lactam antibacterial indicated for the treatment of adult patients with complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible microorganisms. …” Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.
- ¿Cuáles son los efectos secundarios de Zidebactam dihydrate and cefepime hydrochloride?
- La sección «Adverse Reactions» (reacciones adversas) de la etiqueta de la FDA (Zaynich, Wockhardt Suisse USA LLC, 16 de octubre de 2026) comienza así, en inglés: «The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions [see Warnings and Precautions (5.1)] Neurotoxicity [see Warnings and Precautions (5.2)] Clostridiodes difficile Infection [see Warnings and Precautions (5.3)] The most common adverse reactions occurring in ≥ 2% of patients treated with ZAYNICH were diarrhea, headache, hypertension, and hypokalemia.» … Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.
- ¿Qué interacciones tiene Zidebactam dihydrate and cefepime hydrochloride?
- La sección «Drug Interactions» (interacciones) de la etiqueta de la FDA (Zaynich, Wockhardt Suisse USA LLC, 16 de octubre de 2026) comienza así, en inglés: «Aminoglycosides Monitor renal function if aminoglycosides are to be administered with ZAYNICH because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibacterial drugs. 7.2 Diuretics Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.» … Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.
- ¿Zidebactam dihydrate and cefepime hydrochloride tiene una advertencia en recuadro?
- No. Ninguna de las 1 etiquetas de la FDA que encontramos para este medicamento tiene advertencia en recuadro.
- ¿Hay escasez de Zidebactam dihydrate and cefepime hydrochloride?
- La FDA no indica una escasez actual para los productos de este medicamento (datos de la FDA del 13 de noviembre de 2026).
- ¿Se ha retirado del mercado Zidebactam dihydrate and cefepime hydrochloride?
- No aparece ningún retiro vinculado a los productos de este medicamento en los informes de la FDA que usamos.
- ¿Quién fabrica Zidebactam dihydrate and cefepime hydrochloride?
- 1 empresa tiene productos con receta de Zidebactam dihydrate and cefepime hydrochloride en el directorio NDC de la FDA, entre ellas Wockhardt Suisse USA LLC.
Para qué se usa Zidebactam dihydrate and cefepime hydrochloride
Cita de la sección «Indications and Usage» (indicaciones y uso) de la etiqueta aprobada por la FDA. Se muestra en inglés, tal como la publica la FDA.
ZAYNICH is a combination of cefepime, a cephalosporin antibacterial, and zidebactam, a beta-lactamase inhibitor and non-beta-lactam antibacterial indicated for the treatment of adult patients with complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible microorganisms. …
— Etiqueta de la FDA: Zaynich, Wockhardt Suisse USA LLC, vigente desde el 16 de octubre de 2026. Leer la etiqueta completa en DailyMed →
Etiqueta citada: la de la presentación más común (injection, powder, for solution, intravenous), Zaynich, Wockhardt Suisse USA LLC; abarca 1 producto del directorio NDC de la FDA. Las citas sobre efectos secundarios, interacciones, dosis y embarazo de abajo vienen de esta misma etiqueta.
Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.
Advertencia en recuadro
La advertencia en recuadro («caja negra») es la advertencia más seria de la FDA en la etiqueta de un medicamento, para riesgos graves o mortales.
La etiqueta citada arriba no tiene advertencia en recuadro.
Efectos secundarios de Zidebactam dihydrate and cefepime hydrochloride
Cita de la sección «Adverse Reactions» (reacciones adversas) de la etiqueta aprobada por la FDA. Se muestra en inglés. Avise a su médico de cualquier efecto secundario que le preocupe.
The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions [see Warnings and Precautions (5.1)] Neurotoxicity [see Warnings and Precautions (5.2)] Clostridiodes difficile Infection [see Warnings and Precautions (5.3)] The most common adverse reactions occurring in ≥ 2% of patients treated with ZAYNICH were diarrhea, headache, hypertension, and hypokalemia.
Leer más de esta sección
(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Wockhardt Suisse USA LLC at 1-844-367-6548 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. ZAYNICH was evaluated in a phase 3 study in patients with cUTI, including pyelonephritis (also referred to as Trial 1), which included 352 patients treated with ZAYNICH 3 grams (2 grams cefepime and 1 gram zidebactam) every 8 hours infused over 1 hour, and 177 patients treated with the comparator, meropenem, 1 gram every 8 hours, infused over 30 minutes. Patients received treatment for 7 to 10 days. The median duration of therapy was 8 days in both treatment groups in the safety analysis set. The mean age of patients treated with ZAYNICH was 65 years and 61% of patients were 65 years of age or older. Patients were predominantly male (56%) and White (88%). Serious Adverse Reactions and Adverse Reactions Leading to Discontinuation Treatment was discontinued due to adverse reactions in 1.4% (5/352) of patients receiving ZAYNICH and in 1.1% (2/177) of patients receiving meropenem. The adverse reactions resulting in discontinuation of ZAYNICH were anaphylactic reaction, C. difficile colitis, hyperbilirubinemia, drug hypersensitivity, and enterococcal urinary tract infection, each 0.3% (1/352). No deaths were reported. Common Adverse Reactions The most frequently reported adverse reactions (2% or greater) in patients receiving ZAYNICH were diarrhea, hypertension, headache, and hypokalemia. Table 3 lists selected adverse reactions occurring in 2% or greater of patients receiving ZAYNICH in Trial 1. Table 3: Selected Adverse Reactions Occurring in 2% or Greater of cUTI Patients Receiving ZAYNICH in Trial 1 Trial 1 was not designed to evaluate meaningful comparisons of the incidence of adverse reactions in the ZAYNICH and the meropenem treatment groups.
Tabla de la etiqueta
| Adverse Reactions | ZAYNICH (N=352) n (%) | Meropenem (N=177) n (%) |
|---|---|---|
| Diarrhea | 15 (4) | 7 (4) |
| Hypertension Hypertension includes blood pressure inadequately controlled and hypertension. | 12 (3) | 3 (2) |
| Headache | 11 (3) | 9 (5) |
| Hypokalemia | 10 (3) | 2 (1) |
— Etiqueta de la FDA: Zaynich, Wockhardt Suisse USA LLC, vigente desde el 16 de octubre de 2026. Esto es solo una parte de la sección. Leer la etiqueta completa en DailyMed →
Interacciones de Zidebactam dihydrate and cefepime hydrochloride
Cita de la sección «Drug Interactions» (interacciones) de la etiqueta aprobada por la FDA. Se muestra en inglés. Dígale a su farmacéutico todos los medicamentos, vitaminas y productos herbales que toma.
Aminoglycosides Monitor renal function if aminoglycosides are to be administered with ZAYNICH because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibacterial drugs. 7.2 Diuretics Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.
Leer más de esta sección
Monitor renal function when ZAYNICH is concomitantly administered with potent diuretics. 7.3 Drug/Laboratory Test Interactions The administration of ZAYNICH may result in a false-positive reaction for glucose in the urine with certain methods. It is recommended that glucose tests based on enzymatic glucose oxidase reactions be used.
— Etiqueta de la FDA: Zaynich, Wockhardt Suisse USA LLC, vigente desde el 16 de octubre de 2026. Leer la etiqueta completa en DailyMed →
Dosis de Zidebactam dihydrate and cefepime hydrochloride
Cita de la sección «Dosage and Administration» (dosis y administración) de la etiqueta aprobada por la FDA. Se muestra en inglés. Su dosis es la que le receta su médico: no la cambie por su cuenta.
Recommended dosage is ZAYNICH 3 grams (2 grams cefepime and 1 gram zidebactam) every 8 hours by intravenous infusion over 1 hour for 7 to 10 days in adult patients with an estimated glomerular filtration rate (eGFR) greater than or equal to 60 mL/min. (2.1) Dosage adjustment is recommended in adult patients with renal impairment who have an eGFR less than 60 mL/min. (2.2) Administer each intravenous infusion over 1 hour for patients with renal impairment.
Leer más de esta sección
(2.2) Recommended Dosage of ZAYNICH in Adult Patients with Renal Impairment (2.2) eGFR As calculated using 4-variable Modification of Diet in Renal Disease (MDRD) formula. (mL/min) Dose The total duration of treatment is for 7 to 10 days. Dosing Interval 60 to 89 ZAYNICH 3 grams Provides 2 grams cefepime and 1 gram zidebactam. Every 8 hours 30 to 59 ZAYNICH 1.5 grams Provides 1 gram cefepime and 0.5 grams zidebactam. Every 8 hours 15 to 29 ZAYNICH 1.5 grams Every 12 hours 8 to 14 (with or without intermittent hemodialysis (IHD)) On hemodialysis days, recommended dose should be administered after a hemodialysis session. On days, when hemodialysis is not performed, administer recommended dose 24 hours after the previous dose. ZAYNICH 1.5 grams Every 24 hours See Full Prescribing Information for instructions for reconstituting supplied dry powder and subsequent required dilution. (2.3) See Full Prescribing Information for drug compatibilities. (2.4) 2.1 Recommended Dosage The recommended dosage of ZAYNICH is 3 grams (2 grams cefepime and 1 gram zidebactam) administered every 8 hours by intravenous (IV) infusion over 1 hour in adult patients with an eGFR greater than or equal to 60 mL/min. The duration of treatment is 7 days to 10 days. 2.2 Recommended Dosage in Adult Patients with Renal Impairment Table 1 shows the recommended intravenous dosage of ZAYNICH for patients with varying degrees of renal function. Dosage adjustment of ZAYNICH is recommended in adult patients with renal impairment who have an eGFR of less than 60 mL/min, including patients receiving intermittent hemodialysis (IHD) [see Use in Specific Populations (8.6)]. The duration of treatment is 7 days to 10 days. Administer each intravenous infusion over 1 hour. Table 1: Recommended Dosage of ZAYNICH in Adult Patients with Renal Impairment eGFR As calculated using the 4-variable Modification of Diet in Renal Disease (MDRD) formula. (mL/min) Dose The total duration of treatment is for 7 to 10 days. Dosing Interval 60 to 89 ZAYNICH 3 grams Provides 2 grams cefepime and 1 gram zidebactam. Every 8 hours 30 to 59 ZAYNICH 1.5 grams Provides 1 gram cefepime and 0.5 grams zidebactam. Every 8 hours 15 to 29 ZAYNICH 1.5 grams Every 12 hours 8 to 14 (with or without IHD) On hemodialysis days, recommended dose should be administered after a hemodialysis session. On days, when hemodialysis is not performed, administer 24 hours after the previous dose. ZAYNICH 1.5 grams Every 24 hours 2.3 Preparation and Administration Instructions for ZAYNICH Preparation ZAYNICH is supplied as a sterile dry powder in a single-dose vial that must be reconstituted and further diluted prior to intravenous infusion as outlined below. ZAYNICH does not contain preservatives.
Tabla de la etiqueta
| eGFR As calculated using 4-variable Modification of Diet in Renal Disease (MDRD) formula. (mL/min) | Dose The total duration of treatment is for 7 to 10 days. | Dosing Interval |
|---|---|---|
| 60 to 89 | ZAYNICH 3 grams Provides 2 grams cefepime and 1 gram zidebactam. | Every 8 hours |
| 30 to 59 | ZAYNICH 1.5 grams Provides 1 gram cefepime and 0.5 grams zidebactam. | Every 8 hours |
| 15 to 29 | ZAYNICH 1.5 grams | Every 12 hours |
| 8 to 14 (with or without intermittent hemodialysis (IHD)) On hemodialysis days, recommended dose should be administered after a hemodialysis session. On days, when hemodialysis is not performed, administer recommended dose 24 hours after the previous dose. | ZAYNICH 1.5 grams | Every 24 hours |
— Etiqueta de la FDA: Zaynich, Wockhardt Suisse USA LLC, vigente desde el 16 de octubre de 2026. Esto es solo una parte de la sección. Leer la etiqueta completa en DailyMed →
Zidebactam dihydrate and cefepime hydrochloride en el embarazo
Cita de la parte sobre embarazo (Pregnancy) de la etiqueta aprobada por la FDA. Se muestra en inglés. Pregunte a su médico antes de tomar cualquier medicamento si está embarazada o planea estarlo.
Risk Summary There are no data for the use of ZAYNICH, or zidebactam, a component of ZAYNICH, during pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes.
Leer más de esta sección
Available data from published observational studies and case reports over several decades with cephalosporin use, including cefepime, in pregnant women have not established the drug-associated risks of major birth defects, miscarriage or adverse maternal or fetal outcomes. Cefepime Cefepime was not associated with adverse developmental outcomes in rats, mice, or rabbits when administered parenterally during organogenesis. The doses used in these studies were 1.6 (rats), approximately equal to (mice), and 0.3 times (rabbits) the recommended human dose of cefepime in ZAYNICH (see Data). Zidebactam Intravenous administration of zidebactam to pregnant rats during organogenesis showed no evidence of maternal or embryo-fetal toxicity at a dose of 800 mg/kg/day, approximately 5 times the recommended human dose (RHD; 1 gram zidebactam administered every 8 hours) based on plasma area under the concentration-time curve (AUC) comparison. In pregnant rabbits, intravenous administration of zidebactam during organogenesis was associated with increased late fetal resorptions and total fetal loss in two litters at a dose of 600 mg/kg/day (approximately 5 times the RHD) and distended bladder, a fetal anomaly, at zidebactam doses greater than or equal to 300 mg/kg/day (approximately 3 times the RHD). In a pre-postnatal study, zidebactam administered intravenously to pregnant rats during organogenesis and through the lactation period was not associated with maternal toxicity or adverse effects in first- and second-generation offspring at a maternal dose of 800 mg/kg/day, approximately 5 times the RHD (see Data). The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Human Data Cefepime While available studies cannot definitively establish the absence of risk, published data from case-control studies and case reports over several decades have not identified an association with cephalosporin use, including cefepime, during pregnancy and major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Available studies have methodological limitations, including small sample size, retrospective data collection, and inconsistent comparator groups. Animal Data Cefepime Cefepime was not embryocidal and did not cause fetal malformation when administered parenterally during the period of organogenesis to rats at doses up to 1000 mg/kg/day, to mice at doses up to 1200 mg/kg/day, or to rabbits at doses up to 100 mg/kg/day.
— Etiqueta de la FDA: Zaynich, Wockhardt Suisse USA LLC, vigente desde el 16 de octubre de 2026. Esto es solo una parte de la sección. Leer la etiqueta completa en DailyMed →
Cuándo no se debe usar Zidebactam dihydrate and cefepime hydrochloride
Cita de la sección «Contraindications» (contraindicaciones) de la etiqueta aprobada por la FDA. Se muestra en inglés.
ZAYNICH is contraindicated in patients with a known history of serious hypersensitivity to the components of ZAYNICH (cefepime and zidebactam) or other beta-lactam antibacterial drugs [see Warnings and Precautions (5.1)]. ZAYNICH is contraindicated in patients with a known history of serious hypersensitivity to the components of ZAYNICH (cefepime and zidebactam) or other beta-lactam antibacterial drugs. (4)
— Etiqueta de la FDA: Zaynich, Wockhardt Suisse USA LLC, vigente desde el 16 de octubre de 2026. Leer la etiqueta completa en DailyMed →
Sobredosis de Zidebactam dihydrate and cefepime hydrochloride
Cita de la sección «Overdosage» (sobredosis) de la etiqueta aprobada por la FDA. Se muestra en inglés. Si alguien pudo haber tomado demasiado, llame a Poison Help al 1-800-222-1222 (o al 911 en una emergencia).
There is no experience with overdose of ZAYNICH. Patients who receive an overdose should be carefully observed and given supportive treatment. Cefepime and zidebactam can be removed by hemodialysis [see Clinical Pharmacology (12.3)]. No clinical information is available on the use of hemodialysis to treat ZAYNICH overdosage.
Leer más de esta sección
Symptoms of overdose include encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, and coma), myoclonus, seizures, neuromuscular excitability and nonconvulsive status epilepticus [see Warnings and Precautions (5.2), Adverse Reactions (6.2), and Dosage and Administration (2.2)].
— Etiqueta de la FDA: Zaynich, Wockhardt Suisse USA LLC, vigente desde el 16 de octubre de 2026. Leer la etiqueta completa en DailyMed →
Presentaciones y vía de administración
| Formas farmacéuticas | Inyección, polvo, para solución |
|---|---|
| Vía | Intravenosa |
| Productos con receta | 1 en el directorio NDC de la FDA |
| Nombres de marca | Zaynich |
Empresas que tienen este medicamento
Empresas en el directorio NDC de la FDA: la empresa que aparece en el envase (fabricante o distribuidor), con su número de productos con receta.
- Wockhardt Suisse USA LLC1 producto
Historial de aprobación de la FDA
- NDA: Solicitud de nuevo medicamento (NDA): así se aprueba un medicamento nuevo, normalmente de marca.
| Solicitud | Patrocinador | Aprobada | Cambios aprobados después |
|---|---|---|---|
| NDA220787 ZAYNICH | Wockhardt Bio AG | 29 de mayo de 2026 | — |
Escasez
La lista de escasez de la FDA no incluye estos productos.
Retiros del mercado
No aparece ningún retiro vinculado a estos productos (por su código NDC) en los informes de la FDA.
Identificadores oficiales
| RxCUI (RxNorm) | 2744819, 2744824 |
|---|---|
| ID (SPL set ID) de la etiqueta citada | c84e652e-5e76-4568-8812-bd5fa34803b6 |
| Etiquetas de la FDA (SPL) | 1 |
| Solicitudes de la FDA | NDA220787 |
| Principios activos (FDA) | CEFEPIME / ZIDEBACTAM |
Siguientes pasos
- Encuentre una farmacia cerca de ustedPregunte qué precio le corresponde y si su producto está afectado por un retiro
- Últimos retiros de medicamentos de la FDATodos los medicamentos, los más recientes primero
- Wockhardt Suisse USA LLCFabricante o distribuidor
- Todos los medicamentos con receta de la A a la ZBusque por nombre genérico, de marca o en español
Fuentes
- Etiqueta aprobada por la FDA en DailyMed (Biblioteca Nacional de Medicina) — Zaynich, Wockhardt Suisse USA LLC, vigente desde el 16 de octubre de 2026; vía openFDA, datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
- NDC Directory (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
- Drugs@FDA (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
- Drug recall enforcement reports (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 10 de noviembre de 2026, consultados el 14 de noviembre de 2026
- Drug shortages (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
La FDA ofrece los datos de openFDA tal cual; pueden estar incompletos. Guíese siempre por la etiqueta que viene con su medicamento. Buscador de informes de retiros de la FDA →
Informar un error → · Información para fabricantes de medicamentos